DY
RXDX

Dowling & Yahnke’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Dowling & Yahnke’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1.75M Hold
29,613
– – 0.08% 187
2022
Q2 		$836K Buy
29,613
+5,730
+24% +$166K 0.04% 232
2022
Q1 		$902K Hold
23,883
– – 0.04% 233
2021
Q4 		$944K Buy
+23,883
New +$748K 0.05% 229

Other funds holding RXDX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Dowling & Yahnke's RXDX Position: Q3 2022 in Review

Dowling & Yahnke held its Prometheus Biosciences, Inc. Common Stock (RXDX) position steady in Q3 2022 at 29,613 shares worth $1.75M. The position accounts for 0.08% of the portfolio, ranked #187.

Dowling & Yahnke first reported a position in RXDX in Q4 2021 and has held it in 4 quarters since. 144 funds tracked by Wall St. Rank hold RXDX as of Q3 2022.

  • Dowling & Yahnke held 29,613 shares of Prometheus Biosciences, Inc. Common Stock worth $1.75M as of Q3 2022.
  • Dowling & Yahnke left its Prometheus Biosciences, Inc. Common Stock share count unchanged in Q3 2022.
  • Prometheus Biosciences, Inc. Common Stock made up 0.08% of Dowling & Yahnke's portfolio in Q3 2022, its #187 holding.
  • Dowling & Yahnke first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and has held it in 4 quarters since.
  • 144 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q3 2022.

Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.